VVN-001 is under clinical development by Viva Vision Biotech and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase II drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VVN-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VVN-001 is under development for the treatment of dry eye disease. It is a solution form administered by the ophthalmic route. It acts by targeting leukocyte adhesion glycoprotein (LFA1).
Viva Vision Biotech overview
Viva Vision Biotech, a biotechnology company that enables small molecule and biologics drug discovery with leading position in structural biology and biophysics. The company is headquartered in China.
For a complete picture of VVN-001’s drug-specific PTSR and LoA scores, buy the report here.